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A loss-of-function mutation (Q141K, rs2231142) in the ATP-binding cassette, subfamily G, member 2 gene
(ABCG2) has been shown to be associated with serum uric acid levels and gout in Asians, Europeans, and
European and African Americans; however, less is known about these associations in other populations.
Rs2231142 was genotyped in 22,734 European Americans, 9,720 African Americans, 3,849 Mexican Americans,
and 3,550 American Indians in the Population Architecture using Genomics and Epidemiology (PAGE) Study
(2008–2012). Rs2231142 was significantly associated with serum uric acid levels (P = 2.37 × 10−67,
P = 3.98 × 10−5, P = 6.97 × 10−9, and P = 5.33 × 10−4 in European Americans, African Americans, Mexican
Americans, and American Indians, respectively) and gout (P = 2.83 × 10−10, P = 0.01, and P = 0.01 in European
Americans, African Americans, and Mexican Americans, respectively). Overall, the T allele was associated with a
0.24-mg/dL increase in serum uric acid level (P = 1.37 × 10−80) and a 1.75-fold increase in the odds of gout
(P = 1.09 × 10−12). The association between rs2231142 and serum uric acid was significantly stronger in men,
postmenopausal women, and hormone therapy users compared with their counterparts. The association with gout
was also significantly stronger in men than in women. These results highlight a possible role of sex hormones in
the regulation of ABCG2 urate transporter and its potential implications for the prevention, diagnosis, and treat-
ment of hyperuricemia and gout.
ABCG2 protein, human; genetic association studies; gout; meta-analysis; polymorphism, single nucleotide; urate
transporter; uric acid
Abbreviations: ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; CARDIA, Coronary Artery Risk Development
in Young Adults; CHS, Cardiovascular Health Study; CI, confidence interval; EAGLE, Epidemiologic Architecture for Genes
Linked to Environment; NHANES, National Health and Nutrition Examination Survey; OR, odds ratio; PAGE, Population Architec-
ture using Genomics and Epidemiology; SHFS, Strong Heart Family Study; SNP, single-nucleotide polymorphism.
Gout is one of the most common forms of inflammatory
arthritis (1). The prevalence and incidence of gout have
increased in recent decades (2, 3), and it now accounts for
almost 4 million outpatient visits every year in the United
States (4). An elevated concentration of serum uric acid, or
hyperuricemia, is a key risk factor for gout and may also be
a risk factor for cardiovascular disease incidence and mortal-
ity, hypertension, and chronic kidney disease (5–7). Most
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epidemiologic and genetic research on gout and hyperurice-
mia has been conducted in populations of European or
Asian ancestry. In the United States, there have been 2
studies in African Americans (8, 9) but none in Mexican
Americans or American Indians, despite epidemiologic evi-
dence suggesting that the prevalence of gout in African
Americans (830.4 per 100,000 persons) is higher than that
in European Americans (752.9 per 100,000 persons) (3, 10).
Both environmental and genetic factors play important
roles in the etiology of hyperuricemia and gout. Epidemio-
logic studies suggest that men are more likely to develop
gout than women, and the prevalence increases with age in
both sexes, especially among women after menopause (9).
Other known environmental risk factors for hyperuricemia
and gout include obesity, hypertension, type 2 diabetes, use
of diuretics, and alcohol consumption (1). Genetic studies
have demonstrated that serum uric acid levels are highly her-
itable (10). Several genomic loci influencing serum uric acid
levels and the prevalence of gout have been identified in
recent genome-wide association studies, mostly in popula-
tions of European descent (11–16).
A single-nucleotide polymorphism (SNP) consistently
associated with both uric acid and gout is rs2231142,
located on the ATP-binding cassette, subfamily G, member
2 gene (ABCG2; OMIM (Online Mendelian Inheritance in
Man) number 603756). More specifically, the T allele at
rs2231142 has been shown to be associated with increased
serum uric acid levels and odds of gout in persons of Euro-
pean (14, 15, 17, 18), African (14), Japanese (19, 20), and
New Zealand Pacific Island (21) ancestry. More importantly,
the resultant missense polymorphism at codon 141 (gluta-
mine to lysine, Q141K) has been shown to be a loss-of-func-
tion mutation in 2 independent functional studies (22, 23).
Previous studies have shown that the association between
rs2231142 and uric acid and gout is stronger in men than in
women, suggesting that sexmodifies this association (14, 15);
however, the evidence has been inconsistent (18). In addi-
tion, few studies have had sufficiently large sample sizes to
systematically examine potential interactions with other
major risk factors for gout, including age, diabetes, meno-
pausal status, hormone therapy, obesity, alcohol consump-
tion, hypertension, and antihypertensive treatment (14, 18).
Lastly, the association between rs2231142 and serum uric
acid and gout has not been established in Mexican-American
or American Indian populations. Therefore, we conducted a
study within the Population Architecture using Genomics
and Epidemiology (PAGE) Study (24) to determine the
association between rs2231142 and serum uric acid and
gout in 4 general US populations and to specifically examine




Five population-based studies were included as part of the
PAGE Study, including 4 prospective cohort studies—the
Atherosclerosis Risk in Communities (ARIC) Study (25),
the Coronary Artery Risk Development in Young Adults
(CARDIA) Study (26), the Cardiovascular Health Study
(CHS) (27), and the Strong Heart Family Study (SHFS)
(28–30)—and 1 nationally representative, cross-sectional
survey (the National Health and Nutrition Examination
Survey (NHANES)) accessed by the Epidemiologic Archi-
tecture for Genes Linked to Environment (EAGLE) investi-
gators. The current analysis included DNA and data from the
Third National Health and Nutrition Examination Survey
(NHANES III), conducted between 1988 and 1994, and
yearly continuous NHANES data ascertained between 1999
and 2002 (NHANES 1999–2002) (31). The study designs
and data collection methods of these 5 studies are summa-
rized in Web Table 1, available at http://aje.oxfordjournals.
org/. The participants of all 5 studies providedwritten informed
consent. All 5 studies were approved by the institutional
review boards of the participating institutions.
Participants were excluded if they did not identify
themselves as belonging to one of the following 4 groups:
European-American,African-American,Mexican-American,
or American Indian; or if they did not consent to genetic
research. Participants without rs2231142 genotype data or
missing information on uric acid levels or gout were further
excluded from the analysis. In all, the sample sizes for the
analysis of serum uric acid in European Americans, African
Americans, Mexican Americans, and American Indians
were 22,734, 9,720, 3,849, and 3,550, respectively; and the
sample sizes for the analysis of gout in European Ameri-
cans, African Americans, and Mexican Americans were
13,783, 4,271, and 1,373, respectively.
SNP genotyping
In the ARIC Study, the CARDIA Study, the CHS, and the
SHFS, genotyping was performed in the genetic laboratory
at the University of Texas Health Science Center using
TaqMan genotyping assays (Applied Biosystems by Life
Technology, Carlsbad, California). In NHANES III and
NHANES 1999–2002, rs2231142 was genotyped by the
Vanderbilt University DNA Resources Core as part of
EAGLE, using the iPLEX Gold assay (Sequenom, Inc., San
Diego, California). P values for Hardy-Weinberg equilib-
rium were ≥0.01 in all study- and population-specific
groups. The call rates for this marker in all 5 studies were
greater than 95%, except for African Americans in ARIC
(91.2%). In the NHANES III and NHANES 1999–2002
combined study, the genotype concordance rate of blind
duplicated samples using the iPLEX Gold assay was 0.99.
Measurement of outcomes
The primary outcome was serum uric acid level, measured
by means of a uricase method, at the baseline of each study.
The secondary outcome was prevalence of gout. ARIC par-
ticipants (at visit 4, 1996–1998) and NHANES III partici-
pants (1988–1994) were asked, “Has a doctor ever told you
that you had gout?” Participants who answered “yes” were
considered to have gout. Participants who did not know their
gout status were excluded from the gout analyses. The sensi-
tivity of self-reported gout in the ARIC Study was 82% by
reference to a hospital discharge diagnosis of gout or use of
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gout-specific medication as the gold standard (32). In the
CHS (at visit 1, 1989–1993), a participant was considered to
have gout only if he or she was receiving any of the follow-
ing medications at the time of the study examination: allopu-
rinol, probenecid, colchicine, sulfinpyrazone, or colchicine/
probenecid. In the SHFS, the CARDIA Study, and
NHANES 1999–2002, gout status was not assessed.
Assessment of covariates
In all 5 studies, body mass index (BMI) was calculated as
weight in kilograms divided by the square of height in
meters. Obesity status was defined as normal (BMI <25),
overweight (BMI of 25–29.99), or obese (BMI ≥30). Age
groups were defined as young (age ≤50 years) or old (age
>50 years). Alcohol consumption status was defined as self-
reported current drinking or not. Hypertension was defined
as systolic blood pressure ≥140 mm Hg, diastolic blood
pressure ≥90 mm Hg, current use of antihypertensive medi-
cation, or self-reported hypertension. Hypertensive partici-
pants were further categorized into untreated or treated
patients based on their self-reported antihypertensive medi-
cation use. Type 2 diabetes was defined as nonfasting blood
glucose levels ≥200 mg/dL, fasting blood glucose levels
≥126 mg/dL, current use of antidiabetic medication, or self-
reported diabetes.
Self-reported menopausal status (premenopausal vs. post-
menopausal) was used. In the ARIC Study, a woman was
defined as postmenopausal if she 1) had had at least 24 con-
secutive months of amenorrhea, 2) had undergone a bilateral
oophorectomy, or 3) had undergone a hysterectomy and was
aged 55 years or older. In the NHANES, postmenopausal
status was defined as not having had a menstrual period for
at least 24 months. In the SHFS, postmenopausal status was
defined as having not had a menstrual period in the previous
12 months. Women who did not meet postmenopausal crite-
ria were categorized as premenopausal. All women in the
CARDIA Study (age <30 years) were premenopausal, and
all women in the CHS (age ≥65 years) were postmeno-
pausal. Among postmenopausal women, use of hormone
therapy was defined as self-reported current use of estrogen
or estrogen and progestin. The assessment of menopausal
status and hormone therapy use is described in Web Table 1.
Statistical analysis
All study-specific results were stratified by self-reported
race/ethnicity (European-American, African-American,
Mexican-American, or American Indian). In theARIC Study,
the CARDIA Study, CHS, and NHANES, the association
between rs2231142 and either serum uric acid or gout
was examined using unadjusted and multivariable linear or
logistic regression (adjusting for sex, age, BMI, hyperten-
sion, antihypertensive treatment, type 2 diabetes, and
current alcohol drinking). Results from the unadjusted and
multivariable-adjusted models were very similar, and there-
fore we report results from multivariable models. An additive
genetic model was assumed. In the SHFS, a variance com-
ponents-based biometrical model was used to account for
the random effects of kinship (33).
To estimate the population-specific association between
rs2231142 and serum uric acid or gout, population- and
study-specific β coefficients or odds ratios were meta-
analyzed across studies using a fixed-effects model. Since
the associations between rs2144300 and serum uric acid and
gout were consistent across 4 populations, we further meta-
analyzed the data across populations using a random-effects
model to obtain the average effect of the SNP on serum uric
acid and gout.
To detect potential heterogeneity of the association
between rs2144300 and serum uric acid across major gout
risk factors (34), in each study, we first stratified European-
American, African-American, Mexican-American, or Amer-
ican Indian populations into different covariate subgroups
(sex, menopausal status, hormone therapy use, age group,
obesity status, hypertension, type 2 diabetes, and drinking
status) to examine covariate-specific associations with
serum uric acid. The joint estimate of the β coefficient of
rs2231142 for each covariate subgroup was obtained by
pooling results across studies and populations successively
using afixed-effectsmodel.WeusedCochran’sQ test (35, 36)
and a random-effects model to assess heterogeneity across
each stratified covariate. A Q statistic with Phet < 0.05 indi-
cated significant heterogeneity. Parallel heterogeneity analy-
ses were performed for gout, except that we only examined
factors that had significant heterogeneity in the analysis of
serum uric acid level, which included sex, menopausal
status, and hormone therapy.
To examine the potentially confounding effect of popula-
tion stratification, we performed a sensitivity analysis in the
ARIC Study by adjusting for principal components that were
derived from genome-wide association study data (37) and
were associated with the outcomes. For American Indians, to
test for population stratification, we compared the likelihood
of a model in which the association parameters, βb (between-
family genotype score) and βw (within-family genotype
score), were estimated with the likelihood of a model in
which they were constrained to be equal, as would be the case
in the absence of population stratification (38, 39).
Analyses were performed with either Stata 11 (StataCorp
LP, College Station, Texas) or SAS, version 9.2 (SAS Insti-
tute Inc., Cary, North Carolina) in the ARIC Study, the
CHS, and the CARDIA Study. Analyses in EAGLE were
conducted remotely in SAS, version 9.2, using the Analytic
Data Research by Email (ANDRE) portal of the Centers for
Disease Control and Prevention Research Data Center in
Hyattsville, Maryland. Analyses in the SHFS were imple-
mented in the SOLAR (Sequential Oligogenic Linkage
Analysis Routines) software package (version 4.4; South-
west Foundation for Biomedical Research, San Antonio,
Texas) (40, 41). Meta-analyses were conducted using Stata
11. Aggregate statistics related to this work will be available
via the database of Genotypes and Phenotypes (dbGaP) as
part of the PAGE Study.
RESULTS
Baseline characteristics of the 39,853 participants are
given by population in Table 1. In the serum uric acid
analyses, a total of 22,734 European-American, 9,720
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African-American,3,849Mexican-American,and3,550Ameri-
can Indian participants were included. The average serum
uric acid levels in European Americans, African Americans,
Mexican Americans, and American Indians were 5.7 mg/dL,
5.7 mg/dL, 5.2 mg/dL, and 5.1 mg/dL, respectively. The mean
age in years was 53.5 in European Americans, 44.2 in African
Americans, 41.2 in Mexican Americans, and 40.0 in American
Indians. Slightly over half the study population was female,
and the proportion of postmenopausal women ranged from
30.0% to 58.9% across populations. Overall, the prevalence of
gout was 4.4% in European Americans, 5.9% in African
Americans, and 1.0% in Mexican Americans. Baseline char-
acteristics of the population- and study-specific samples are
shown in Web Table 2.
Association between rs2231142 and serum uric acid
levels and gout
Frequencies of the T allele in rs2231142 were 0.11 in
European Americans, 0.03 in African Americans, 0.19 in
Mexican Americans, and 0.20 in American Indians
(Table 2). SNP rs2231142 was consistently associated with
serum uric acid levels across studies (Phet > 0.05). The
population- and study-specific results are shown in Web
Table 3. In the meta-analysis, each copy of the T allele was
significantly associated with an increase in serum uric acid
concentration of 0.31 mg/dL (P = 2.37 × 10−67) in European
Americans, 0.21 mg/dL (P = 3.98 × 10−5) in African Ameri-
cans, 0.22 mg/dL (P = 6.97 × 10−9) in Mexican Americans,
and 0.18 mg/dL (P = 5.33 × 10−4) in American Indians
(Table 2). After pooling of data across populations, the joint
estimate of the β coefficient of rs2231142 associated with
serum uric acid level was 0.24 (95% confidence interval
(CI): 0.17, 0.31; P = 1.37 × 10−80).
Similarly, a consistent association was observed with gout
across studies (Phet > 0.05) (Web Table 3). In the meta-
analysis, each copy of the T allele was significantly associ-
ated with an approximately 2-fold increase in the odds of
gout: The odds ratios were 1.71 (P = 2.83 × 10−10) in Euro-
pean Americans, 1.80 (P = 0.01) in African Americans, and
2.97 (P = 0.01) in Mexican Americans (Table 2). After
pooling across populations, the joint estimate of the odds
Table 1. Characteristics of 39,853 Participants in an Analysis of the Relationship of the ABCG2 rs2231142 PolymorphismWith Uric Acid and
Gout, by Race/Ethnicity, PAGE Study, 2008–2012
Race/Ethnicity
European-American African-American Mexican-American American Indian
Mean (SD) % Mean (SD) % Mean (SD) % Mean (SD) %
Uric acid analysis (n = 22,734) (n = 9,720) (n = 3,849) (n = 3,550)
Serum uric acid level, mg/dL 5.7 (1.5) 5.7 (1.6) 5.2 (1.4) 5.1 (1.5)
Body mass indexa 26.7 (5.1) 28.2 (6.3) 27.7 (5.7) 32.3 (7.9)
Age, years 53.5 (11.1) 44.2 (12.3) 41.2 (18.7) 39.96 (17.0)
Female sex 54.5 58.9 51.1 52.0
Postmenopausal 58.9 40.6 37.0 30.0
Hormone therapyb 15.5 9.6 4.0 9.0
Current alcohol drinker 64.8 50.8 59.6 58.0
Hypertension 32.3 39.5 28.0 32.0
Antihypertensive treatment 53.3 41.1 12.2 20.0
Type 2 diabetes 8.6 12.5 11.9 23.0
Gout analysis (n = 13,783) (n = 4,271) (n = 1,373) (N/A)
Gout prevalence 4.4 5.9 1.0 N/A
Body mass index 26.7 (4.8) 28.7 (6.1) 27.0 (5.6) N/A
Age, years 57.9 (7.2) 50.4 (10.1) 37.1 (18.7) N/A
Female sex 56.1 61.9 50.6 N/A
Postmenopausal 66.8 52.5 27.4 N/A
Hormone therapy 19.3 14.7 7.6 N/A
Current alcohol drinker 61.5 39.2 57.8 N/A
Hypertension 33.8 47.1 24.0 N/A
Antihypertensive treatment 61.2 54.9 7.9 N/A
Type 2 diabetes 8.9 13.4 10.6 N/A
Abbreviations: N/A, not applicable; PAGE, Population Architecture using Genetics and Epidemiology; SD, standard deviation.
a Weight (kg)/height (m)2.
b Self-reported current use of estrogen or estrogen and progestin (among postmenopausal women).
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ratio for the association of rs2231142 with gout was 1.75
(95% CI: 1.50, 2.04; P = 1.09 × 10−12).
Association between rs2231142 and serum uric acid
levels by subgroup
In each of the 4 populations studied, the association
between rs22311432 and serum uric acid level was con-
sistently stronger in men than in women (Figure 1). Probably
because of smaller sample sizes in the non-European-
American populations, the sex difference in the genetic effects
was statistically significant only in the European Americans
(Phet = 0.001). After pooling of data across populations, a sig-
nificantly stronger association between rs2231142 and serum
uric acid level was observed in men (n = 18,223; β = 0.35,
P = 3.9 × 10−52) than in women (n = 21,360; β = 0.20,
P = 6.35 × 10−12), with significant heterogeneity between
these 2 estimates (Phet = 1.64 × 10
−5; Table 3).
In addition, the association between rs2231142 and serum
uric acid level was also stronger in postmenopausal women
(n = 11,083; β = 0.27, P = 6.06 × 10−10) than in premeno-
pausal women (n = 8,040; β = 0.14, P = 3.10 × 10−5), with
significant heterogeneity (Phet = 0.02). Among postmeno-
pausal women, hormone therapy users showed a stronger
association (n = 1,930; β = 0.41, P = 2.59 × 10−10) than non-
users (n = 8,468; β = 0.25, P = 2.86 × 10−13), with significant
heterogeneity (Phet = 0.03). We also tested heterogeneity in
the association between rs2231142 and serum uric levels
across age groups, obesity status, hypertension, type 2 diabe-
tes, and drinking status but did not observe any significant
heterogeneity (Table 3). The population-, study-, and covari-
ate-specific β coefficients for the association of rs2231142
with serum uric acid (for sex, menopausal status, and
hormone therapy use) are shown in Web Tables 4–6.
Association between rs2231142 and gout by subgroup
Table 4 summarizes the association between rs2231142
and the prevalence of gout by sex, menopausal status, and
hormone therapy use. Across the 4 populations, the associa-
tion between rs2231142 and prevalent gout was significantly
stronger in men (n = 6,620; odds ratio (OR) = 2.03,
P = 1.53 × 10−13) than in women (n = 9,018; OR = 1.37,
P = 0.03; Phet = 0.03). Among women, this association was
statistically significant only in postmenopausal women
(n = 6,985; OR = 1.45, P = 0.03), not in premenopausal





Uric Acid Level Gout
βb 95% CI P Valuec ORd 95% CI P Valuec
European-American 0.11 0.31 0.28, 0.50 2.37 × 10−67 1.71 1.45, 2.02 2.83 × 10−10
African-American 0.03 0.21 0.11, 0.32 3.98 × 10−5 1.80 1.14, 2.84 0.01
Mexican-American 0.19 0.22 0.16, 0.29 6.97 × 10−9 2.97 1.25, 11.04 0.01
American Indian 0.20 0.18 0.08, 0.29 5.33 × 10−4 N/A N/A N/A
Overall effect size 0.24 0.17, 0.31 1.37 × 10−80 1.75 1.50, 2.04 1.09 × 10−12
Abbreviations: CI, confidence interval; N/A, not applicable; OR, odds ratio; PAGE, Population Architecture using Genetics and Epidemiology.
a Minor allele on the forward strand of the human genome reference sequence of National Center for Biotechnology Information build 37.1. The
minor allele was the nonreference allele in all analyses.
b Increase in serum uric acid level (mg/dL) associated with each copy of the T allele in rs2231142.
c P value for the multivariable linear (β) or logistic regression (OR) analysis adjusting for sex, age, body mass index, hypertension,
antihypertensive treatment, type 2 diabetes, and current alcohol drinking.
d Increase in the odds of gout associated with each copy of the T allele in rs2231142.
Figure 1. Sex-specific (squares) and pooled (diamonds)
associations between rs2231142 and serum uric acid levels in the
Population Architecture using Genetics and Epidemiology (PAGE)
Study, by race/ethnicity and sex, 2008–2012. Beta coefficients (β)
and 95% confidence intervals (CIs) were obtained from a multi-
variable linear regression model adjusting for sex, age, body mass
index, hypertension, antihypertensive treatment, type 2 diabetes, and
current alcohol drinking. I2 and Phet values were obtained from
Cochran’s Q test using a random-effects model. The size of each
square is proportional to the percent weight that each race/ethnicity-
and sex-specific group contributed in the overall association. The
diamond represents the pooled β coefficient for each population. Bars,
95% CI.
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women (n = 2,033; OR = 0.96, P = 0.94; Phet = 0.43). Lastly,
among postmenopausal women, the association between
rs2231142 and gout was significant only in non–hormone
therapy users (n = 5,014; OR = 1.53, P = 0.03), not in
hormone therapy users (n = 1,320; OR = 1.06, P = 0.39;
Phet = 0.08). The population-, study-, and covariate-specific
odds ratios for the association of rs2231142 with gout are
shown in Web Tables 7–9.
In the sensitivity analysis conducted in the ARIC Study, the
results obtained from models with and without adjustment for
principal components did not differ, and the causal inference
was not changed in European Americans and African Ameri-
cans. For American Indians, as implemented in SOLAR, the
tests for population stratification for rs2231142 from previous
quantitative-trait linkage disequilibrium tests were not signifi-
cant (P > 0.05) (38, 39).
DISCUSSION
In a meta-analysis of 39,853 persons from 4 different
population-based samples (European Americans, African
Americans, Mexican Americans, and American Indians),
we demonstrated that the functional variant rs2231142
(Q141K) in the ABCG2 gene was significantly associated
with both serum uric acid level (P = 2.37 × 10−67,
P = 3.98 × 10−5, P = 6.97 × 10−9, and P = 5.33 × 10−4 in
European Americans, African Americans, Mexican Ameri-
cans, and American Indians, respectively) and the odds of
Table 3. Associations Between the ABCG2 rs2231142 Polymorphism and Serum Uric Acid Level According to




βa 95% CI P Valueb Phetc
Sex 1.64 × 10−5
Male 18,223 0.35 0.31, 0.40 3.9 × 10−52
Female 21,360 0.20 0.15, 0.26 6.35 × 10−12
Menopausal status 0.02
Premenopausal 8,040 0.14 0.07, 0.20 3.10 × 10−5
Postmenopausal 11,083 0.27 0.18, 0.35 6.06 × 10−10
Hormone therapyd 0.03
No 8,468 0.25 0.18, 0.31 2.86 × 10−13
Yes 1,930 0.41 0.28, 0.54 2.59 × 10−10
Age group, years 0.14
Young (≤50) 18,656 0.24 0.21, 0.28 5.32 × 10−39
Old (>50) 20,927 0.30 0.23, 0.37 5.03 × 10−18
Obesity statuse 0.87
Normal 14,813 0.27 0.23, 0.31 1.10 × 10−36
Overweight 13,879 0.25 0.17, 0.33 1.92 × 10−9
Obese 11,161 0.29 0.17, 0.40 1.96 × 10−6
Hypertension 0.19
Normotensive 26,357 0.24 0.19, 0.29 7.69 × 10−22
Untreated hypertension 5,361 0.22 0.13, 0.31 1.96 × 10−6
Treated hypertension 7,906 0.35 0.23, 0.46 6.04 × 10−9
Type 2 diabetes 0.72
No 35,241 0.26 0.20, 0.31 8.02 × 10−21
Yes 4,365 0.28 0.17, 0.39 8.63 × 10−7
Current alcohol drinking 0.93
No 12,747 0.29 0.19, 0.38 1.49 × 10−9
Yes 18,880 0.28 0.24, 0.32 1.95 × 10−47
Abbreviations: BMI, body mass index; CI, confidence interval; PAGE, Population Architecture using Genetics and
Epidemiology.
a Increase in serum uric acid level (mg/dL) associated with each copy of the T allele in rs2231142.
b P value for the multivariable linear regression analysis adjusting for sex, age, body mass index, hypertension,
antihypertensive treatment, type 2 diabetes, and current alcohol drinking.
c P value from Cochran’sQ test using a random-effects model to assess heterogeneities across subgroups.
d Self-reported current use of estrogen or estrogen and progestin (among postmenopausal women).
e Normal, BMI (weight (kg)/height (m)2) <25; overweight, BMI 25–29.99; obese, BMI ≥30.
928 Zhang et al.
Am J Epidemiol. 2013;177(9):923–932
gout (P = 2.83 × 10−10, P = 0.01, and P = 0.01 in European
Americans, African Americans, and Mexican Americans,
respectively). After pooling of data across populations, each
copy of the T allele in rs2231142 was associated with a
0.24-mg/dL increase in serum uric acid levels (95% CI:
0.17, 0.31; P = 1.37 × 10−80) and a 1.75-fold increase in the
odds of gout (95% CI: 1.50, 2.04; P = 1.09 × 10−12). More-
over, there was a significantly stronger association between
rs2231142 and both serum uric acid and gout in men com-
pared with women. Lastly, we also observed heterogeneity
in the association between rs2231142 and serum uric acid
levels across menopausal and hormone therapy status cate-
gories, with a stronger association in postmenopausal
women and hormone therapy users than in their counter-
parts.
Our study showed, for the first time, that rs2231142 is
associated with serum uric acid levels and gout in Mexican
Americans and American Indians, 2 admixed populations
that had not been previously studied. Despite differences in
minor allele frequencies at this variant across populations
(minor allele frequencies ranging from 0.03 to 0.20), the
associations between rs2231142 and the phenotypes were
direction-consistent and robust across populations. More-
over, our study confirmed the previously observed heteroge-
neity between men and women in the association between
rs2231142 and uric acid in our European-American samples
and further demonstrated such heterogeneity in African
Americans, Mexican Americans, and American Indians.
The inclusion of a large proportion of postmenopausal
women (>30.0%) and postmenopausal women receiving
hormone therapy (ranging from 4.0% to 15.5%) in the
serum uric acid analysis provided adequate statistical power
to examine heterogeneity across categories of menopausal
status and hormone therapy use, which had not been
assessed previously. Lastly, similar to previous studies, the
association between rs2231142 and serum uric acid level
did not differ significantly by age group, obesity status, dia-
betes, hypertension, or alcohol drinking status, which sug-
gests either a lack of effect modification or very modest
effect modification by these major gout risk factors, which
the current study did not have adequate statistical power to
discover. With a sample size of 39,853 in the present study
and assuming that 50% of the population is exposed to the
environmental factor, we had 80% power to detect an inter-
action effect as low as 0.10 (the difference in the β coeffi-
cients between men and women was 0.15 in our uric acid
analysis) (42).
The ABCG2 protein, encoded by the ABCG2 gene, has
been shown to mediate renal urate secretion as a urate efflux
transporter in the (luminal) brush-border membrane of
kidney proximal tubule cells (23). The Q141K (rs2231142)
polymorphism occurs in a highly conserved region of the
gene and has been shown to be a loss-of-function mutation
in 2 independent functional studies (22, 23). Moreover,
several previous studies have reported regulation of the
ABCG2 protein by estrogen. A series of studies showed that
the ABCG2 protein has a putative estrogen response
element (43) and that estrogens, along with their derivatives,
antagonists and agonists, can regulate ABCG2 transporter
activity in K562 human leukemia cells (44, 45), human pla-
cental BeWo cell lines (46), an ex vivo blood-brain barrier
model from rats and mice (47), and mouse liver in vivo (48).
The direction of regulation varies with the differences in sex
hormones, model organisms, target organs, and substrates
used to test ABCG2 protein function. One study found that
higher expression of ABCG2 in kidney tissues from male
rats appeared to be due to a suppressive effect of estradiol,
because castration of the males had no effect on kidney
ABCG2 mRNA levels while ovariectomy of the female rats
led to increased expression (49). If these results from model
Table 4. Associations Between the ABCG2 rs2231142 Polymorphism and Gout According to Major Risk Factors




ORa 95% CI P Valueb Phetc
Sex 0.03
Male 6,620 2.03 1.68, 2.45 1.53 × 10−13
Female 9,018 1.37 1.03, 1.82 0.03
Menopausal status 0.43
Premenopausal 2,033 0.96 0.38, 2.47 0.94
Postmenopausal 6,985 1.45 1.04, 2.02 0.03
Hormone therapyd 0.08
No 5,014 1.53 1.03, 2.27 0.03
Yes 1,320 1.06 0.93, 1.21 0.39
Abbreviations: CI, confidence interval; OR, odds ratio; PAGE, Population Architecture using Genetics and
Epidemiology.
a Increase in the odds of gout associated with each copy of the T allele in rs2231142.
bP value for the multivariable logistic regression analysis adjusting for sex, age, body mass index, hypertension,
antihypertensive treatment, type 2 diabetes, and current alcohol drinking.
c P value from Cochran’sQ test using a random-effects model to assess heterogeneities across subgroups.
d Self-reported current use of estrogen or estrogen and progestin (among postmenopausal women).
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systems are reflective of the human kidney, one might
expect that the consequence of the Q141K loss-of-function
polymorphism would be relatively less in persons with high
estrogen levels (they had decreased ABCG2 mRNA expres-
sion to begin with) compared with those with low estrogen
levels. Our results were consistent in that the magnitudes of
the associations for both serum uric acid and gout were
smaller in women compared with men and in premeno-
pausal women compared with postmenopausal women.
However, a significantly stronger association with uric acid
in hormone therapy users compared with nonusers was not
expected based on previous animal data.
Several methodological issues may explain this apparent
inconsistency. First, the hormone therapy measurement in
our study was based on self-report. We did not have infor-
mation on specific regimen, duration, or adherence. In addi-
tion, the heterogeneity between hormone therapy users and
nonusers may be due not to their difference in sex hormone
levels but to other factors which can influence the use of
hormone therapy. Moreover, it is possible that endogenous
and exogenous hormones may interact differently with the
ABCG2 protein. Lastly, it is also possible that the interaction
between ABCG2 protein and estrogen is different in various
animal models, including humans. Thus, the statistical inter-
action between rs2231142 and hormone therapy use will
need to be replicated in other populations and further investi-
gated at the biological level.
The results of the current study should be interpreted with
some limitations in mind. First, this was a cross-sectional
study. While it is clear that genes can influence serum uric
acid levels and gout and the reverse cannot be true, the same
cannot be assumed for the relationship between the pheno-
types and the gout risk factors examined, except for sex.
Second, the statistical power of the gout analysis was limi-
ted because of the smaller sample sizes, the dichotomized
nature of the trait, differences in study-specific definitions of
gout, and the limitation of self-reported gout. Third, medica-
tions which may affect uric acid levels were not considered
in the analyses; however, this may not have confounded our
results, because the use of such medications is unlikely to be
associated with genotype status at rs2231142. Lastly, we
were not able to assess whether the observed association in
Mexican Americans was due to confounding by population
stratification; however, this is not likely to be the case,
because rs2231142 is a functional polymorphism and the
results of our sensitivity analyses in the other 3 populations
showed that adjustment for population substructure did not
alter the associations between rs2231142 and outcomes.
There are several aspects of the study that strengthened
our findings. First, we used a large, multiethnic sample with
data collected from 5 well-characterized population-based
studies in the United States, providing unbiased estimates of
allele frequencies and effect sizes across the general popula-
tion. Second, the phenotypes and the covariates were care-
fully harmonized across the studies, which minimized the
potential decrease in power due to study heterogeneities.
Third, given the consistency of associations between
rs2231142 and serum uric acid and gout across the 4 popula-
tions, we were able to meta-analyze across the populations
to obtain the average effect and to increase statistical power.
Lastly, the Q141K variant is a well-studied functional poly-
morphism, thus providing a strong a priori hypothesis and
biological plausibility. Moreover, our statistical interaction
results are supported by some biological mechanisms,
though more direct evidence is still needed.
In conclusion, the common polymorphism rs2231142,
which leads to a change from glutamine to lysine in codon
141 (Q141K) of the ABCG2 gene, is significantly associated
with elevated serum uric acid levels and increased preva-
lence of gout in European Americans, African Americans,
Mexican Americans, and Americans Indians. In addition,
this SNP appears to have a differential effect on serum uric
acid levels and gout prevalence by sex and heterogeneous
associations across menopausal status and hormone therapy
use with uric acid levels, which sheds light on sex and age
differences in susceptibility to gout. More research is war-
ranted on the possible role of sex hormones in the regulation
of ABCG2 urate transporter and the potential implications
for the prevention, diagnosis, and treatment of hyperurice-
mia and gout.
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